Morgan Stanley analyst Jeffrey Hung downgraded Repare Therapeutics to Equal Weight from Overweight with a price target of $15, down from $28. The analyst downgraded the shares after extending the time it will take for RP-6306 to reach the market. The firm believes it will hit the market in 2028 versus a previous estimate of 2026.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on RPTX: